Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

5.53

Margin Of Safety %

17

Put/Call OI Ratio

0.32

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

1.05

Price

169.08

Target Price

203

Analyst Recom

2.06

Performance Q

3.93

Upside

-138.6%

Beta

1.66

Ticker: CRL




17 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23CRL219.661.340.705472
2026-01-26CRL222.311.343.005515
2026-01-27CRL219.491.342.255509
2026-01-28CRL216.941.341.835514
2026-01-29CRL211.861.340.015522
2026-01-30CRL210.461.160.005903
2026-02-02CRL213.180.951.386499
2026-02-04CRL201.550.810.606237
2026-02-05CRL183.570.8123.576235
2026-02-06CRL189.320.990.196708
2026-02-09CRL185.640.950.717270
2026-02-10CRL181.270.950.137277
2026-02-11CRL165.980.921.547389
2026-02-12CRL158.720.810.287359
2026-02-13CRL161.310.730.057808
2026-02-18CRL157.930.381.2116113
2026-02-19CRL164.360.3240.0016972
DateSymbolLatestP/C OIP/C VolTotal OI
17 items Current Page1 of 1




17 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23CRL219.65-11.8597.610.24
2026-01-26CRL222.36-11.8616.010.24
2026-01-27CRL219.53-11.8601.610.24
2026-01-28CRL216.75-11.8601.610.24
2026-01-29CRL211.73-11.8595.310.24
2026-01-30CRL210.56-11.8605.810.24
2026-02-02CRL213.41-11.8616.710.24
2026-02-03CRL201.40-11.8577.410.24
2026-02-04CRL201.54-11.8609.210.24
2026-02-05CRL183.61-11.8558.710.24
2026-02-06CRL189.17-11.8625.510.24
2026-02-09CRL185.64-11.8598.410.24
2026-02-10CRL181.21-11.8595.510.24
2026-02-12CRL158.76-11.8585.410.24
2026-02-18CRL157.84-11.8606.510.24
2026-02-19CRL164.26-11.8- 10.24
2026-02-20CRL169.08-9.1- 10.96
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
17 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23CRL-0.282.195.29
2026-01-26CRL-0.284.095.29
2026-01-27CRL-0.284.095.29
2026-01-28CRL-0.284.095.83
2026-01-29CRL-0.284.095.83
2026-01-30CRL-0.284.095.83
2026-02-02CRL-0.283.985.83
2026-02-03CRL-0.283.985.83
2026-02-04CRL-0.283.985.83
2026-02-05CRL-0.283.985.83
2026-02-06CRL-0.283.985.83
2026-02-09CRL-0.193.835.83
2026-02-10CRL-0.193.835.83
2026-02-11CRL-0.193.835.53
2026-02-12CRL-0.193.835.53
2026-02-13CRL-0.193.835.53
2026-02-17CRL-0.194.345.53
2026-02-18CRL-0.194.345.53
2026-02-19CRL-0.194.345.53
2026-02-20CRL-0.194.345.53
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

2.13

Avg. EPS Est. Next Quarter

3

Insider Transactions

-0.19

Institutional Transactions

4.34

Beta

1.66

Average Sales Estimate Current Quarter

980

Average Sales Estimate Next Quarter

1024

Fair Value

197.01

Quality Score

47

Growth Score

53

Sentiment Score

55

Actual DrawDown %

63.3

Max Drawdown 5-Year %

-78.2

Target Price

203

P/E

Forward P/E

14.05

PEG

1.67

P/S

2.07

P/B

2.63

P/Free Cash Flow

16.04

EPS

-2.96

Average EPS Est. Cur. Y​

10.96

EPS Next Y. (Est.)

12.01

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3.59

Relative Volume

1.86

Return on Equity vs Sector %

-31.5

Return on Equity vs Industry %

-13.4

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.07

EBIT Estimation

Charles River Laboratories Inte
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 18300
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
stock quote shares CRL – Charles River Laboratories International, Inc. Stock Price stock today
news today CRL – Charles River Laboratories International, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CRL – Charles River Laboratories International, Inc. yahoo finance google finance
stock history CRL – Charles River Laboratories International, Inc. invest stock market
stock prices CRL premarket after hours
ticker CRL fair value insiders trading